Friedrich Schiller University
Jena, Thuringia, 07743, Germany
NCT Number: NCT01316198
The objective of the study was to investigate the influence of a intervention with lutein und zeaxanthin from crucifers on the optical density of the macular pigment of patients with non exudative age-related maculopathy. It is hypothesized that the applied study beverage elevates plasma concentrations of the administered xanthophylls and the optical density after 4 weeks of intervention.
Looking for future studies?
Notify MeAll sexes
Interventional
Not applicable
Jena, Thuringia, 07743, Germany
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
10 subjects consume for 4 weeks a beverage containing 10 mg lutein and 3 mg zeaxanthin per day
10 subjects consume for 4 weeks a placebo beverage without any lutein and zeaxanthin
Time frame: 10 weeks
Time frame: 10 weeks
Time frame: 10 weeks
University of Jena
Other
Alteration of Optical Density and Plasma Xanthophylls After Short Term Supplementation With Macular Carotenoids in Patients With AMD
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT02941263
Age-Related Macular Degeneration, Eye Diseases
Bethesda, Maryland, United States
View Trial DetailsNCT01352975
Age-Related Macular Degeneration, Eye Diseases
Bethesda, Maryland, United States
View Trial DetailsNCT06190093
Age-Related Macular Degeneration, Eye Diseases
Arcadia, California, United States
View Trial DetailsNCT06164587
Age-Related Macular Degeneration, Eye Diseases
Loma Linda, California, United States
View Trial Details